Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
CAR-T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Philadelphia Positive Acute Lymphoblastic Leukemia
1 trial -
CCTA, CT-MPI, DSA, FFR
The First People's Hospital of Lianyungang
Coronary Microvascular Disease
1 trial -
CD19 CAR-T cells infusion
The First People's Hospital of Lianyungang
Non Hodgkin Lymphoma
1 trial -
CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Childhood Asthma
1 trial -
CM-336 BCMA/CD3 bispecific antibody
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AL Amyloidosis
1 trial -
CMGV
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Recurrent Adult Acute Myeloid Leukemia
1 trial -
CMOP+Chidamide
The First People's Hospital of Lianyungang
Newly Diagnosed Peripheral T-cell Lymphoma
1 trial -
COVID Convalescent Plasma
Xiyuan Hospital of China Academy of Chinese Medical Sciences
COVID-19
1 trial -
CT colonoscopy(normal dose)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Polyps
1 trial -
CT scan
United Therapeutics Europe Ltd
Hospital-acquired Pneumonia
1 trial -
CT three-dimensional reconstruction
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Rectal Cancer
1 trial -
CT-FFR assessment
The First People's Hospital of Lianyungang
Coronary Artery Disease
1 trial -
CT0590 CAR T Cells
The First People's Hospital of Lianyungang
Relapsed and/or Refractory Multiple Myeloma
1 trial -
CT0594CP
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
CYP2C19 genotype testing
Beijing Anzhen Hospital
Angina, Stable
1 trial -
Cadonilimab
The First People's Hospital of Lianyungang
Locally Advanced Esophageal Squamous Cell Carcinoma
1 trial -
Calcium Carbonate 1500 Mg with Vitamin D
Hospital Authority, Hong Kong
Thyroid Neoplasm
1 trial -
Calcium supplement
Hospital Authority, Hong Kong
Hypocalcemia in Pregnancy
1 trial -
Canagliflozin
The First People's Hospital of Lianyungang
Type 2 Diabetes Mellitus With Complication
1 trial -
Carbon Nanoparticle Suspension Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
Cardiopulmonary Exercise Testing
Esperion Therapeutics
Intrauterine Growth Restriction
1 trial -
Carrelizumab
The First People's Hospital of Lianyungang
Cholangiocarcinoma
1 trial -
Carrelizumab
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Cefazolin with Daptomycin
Hospital Authority, Hong Kong
Periprosthetic Joint Infection
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources